EUVIMEDEUVIMED entdecken
Crossref

Daratumumab monotherapy versus bortezomib-based regimen in patients with biopsy-proven renal AL amyloidosis ineligible for Bone Marrow Transplant

Roccatello Dario, Sciascia Savino iD, Antonella Barreca, Rabajoli Gianluca, Del Vecchio Giulio, Rossi Daniela, Rubini Elena, Fenoglio Roberta

Nephrology Dialysis Transplantation · 20.05.2026

DOI: 10.1093/ndt/gfag117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.05.2026. Verfasst von Roccatello Dario und 7 weiteren Autor:innen. Beteiligte Einrichtung: University Center of Excellence (ERK-Net, ERN-Reconnet and ERN-RITA Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and R…. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Piedmont and Aosta Valley.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bortezomib-based regimens have long represented the standard option for Systemic light-chain (AL) amyloidosis amyloidosis, whereas daratumumab has recently emerged as a promising alternative. We compared two consecutive single-center cohorts of frail, non-transplant-eligible patients treated with either bortezomib-based therapy or daratumumab monotherapy, assessing clinical and renal outcomes.

Methods

Thirty-one patients with renal AL amyloidosis were included: 17 received bortezomib-based regimens (historical cohort) and 14 received daratumumab monotherapy (prospective cohort). All had biopsy-confirmed renal amyloid deposition and were transplant-ineligible. Hematologic and organ responses followed International Society of Amyloidosis criteria.

Results

Baseline characteristics were similar between cohorts. Hematologic response rates were 57.1% with bortezomib versus 92.8% with daratumumab (P = .03), with complete responses in 28.6% and 57.1%, respectively. Renal response occurred in 35% of bortezomib-treated patients versus 71.4% with daratumumab (P = .04). Proteinuria declined by 76% in bortezomib responders and 72% in daratumumab responders, with stable creatinine in both groups. Among patients achieving dual hematologic and renal responses, 12-month survival was 100% in the daratumumab cohort versus 71% in the historical group. At last follow-up, renal survival was 67% versus 86%, and overall survival 47% versus 79% (P = .08). Major infections occurred in 18% and 14%, respectively. Repeat biopsies showed stabilization or regression of amyloid in 62% of daratumumab-treated versus 20% of historical cases.

Conclusions

In frail, Autologous Stem Cell Transplant (ASCT)-ineligible patients with biopsy-proven renal AL amyloidosis, daratumumab monotherapy yielded higher hematologic and renal response rates compared with bortezomib-based regimens. These findings support early anti-CD38 therapy as a potential strategy to improve renal preservation and survival, warranting confirmation in multicenter trials.

Schlagwörter

Stichwörter der Autor:innen

Daratumumabamyloidosisproteinuriarenal Biopsyrenal histology

Autor:innen und Institutionen

  • University Center of Excellence (ERK-Net, ERN-Reconnet and ERN-RITA Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network…
  • Division of Pathology, Città Della Salute e Della Scienza Hospital and University of Turin, Turin, Italy.

ORCID-Profile: Sciascia Savino

Förderung

  • Piedmont and Aosta Valley

Zitieren

APA

Dario, R., Savino, S., Barreca, A., Gianluca, R., Giulio, D. V., Daniela, R., Elena, R., & Roberta, F. (2026). Daratumumab monotherapy versus bortezomib-based regimen in patients with biopsy-proven renal AL amyloidosis ineligible for Bone Marrow Transplant. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag117

Vancouver

Dario R, Savino S, Barreca A, Gianluca R, Giulio DV, Daniela R, et al. Daratumumab monotherapy versus bortezomib-based regimen in patients with biopsy-proven renal AL amyloidosis ineligible for Bone Marrow Transplant. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag117

BibTeX
@article{Dario2026,
  author = {Dario, Roccatello and Savino, Sciascia and Barreca, Antonella and Gianluca, Rabajoli and Giulio, Del Vecchio and Daniela, Rossi and Elena, Rubini and Roberta, Fenoglio},
  title = {Daratumumab monotherapy versus bortezomib-based regimen in patients with biopsy-proven renal AL amyloidosis ineligible for Bone Marrow Transplant},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag117}
}
Kostenlos starten →